Linde (LIN) at 29.7 Times Earnings: Cheap Only Against Itself
On July 31, 2026, Linde reported quarterly revenue growth of 9.3%, its best in the six quarters I can see, and the shares fell 5.9% that day. That is an odd reaction to a good report, and it is the puzzle I want to work through here. Linde trades around $460.40 as I write this, 15.7% below its 52-week high of $546, at 29.7 times trailing earnings.
My view is that Linde is cheap only against its own past. Against the group of specialty chemical companies it sits about where the group does, and against the market it is still a premium stock. The premium is defensible, because the business sells a product customers cannot easily switch away from, but the price no longer assumes that the growth of the last two quarters will be given back. I think that is the right way to read the setup, with one condition I will come back to.
Oxygen, contracts and the mix
Linde makes oxygen, nitrogen, hydrogen and other industrial gases and sells them to hospitals, steel mills, chip factories and food producers. As the company describes its business, much of the supply sits under long-term contracts, often with a plant built next to the customer. I have not audited those contract terms, so treat the exact structure as something to confirm in the annual report. What the reported numbers do show is a very stable profit stream.
Americas was 44.0% of second-quarter 2026 revenue, or about $4.08 billion. Europe, the Middle East and Africa was 24.8%, Asia Pacific 20.1%, Engineering 6.7% and other 4.4%. The Engineering unit builds plants, so I would expect its revenue to lump up and down with project timing, and it is the part of the mix I would call least recurring. That is the least repeatable slice.
The gas supply business is the steady part. It is also why the mix reads as more stable than the average industrial’s, with roughly 93 cents of every revenue dollar coming from outside Engineering.
Six quarters of faster growth
The revenue growth path is the strongest part of the bull case. Year over year, the six quarters ending in March 2025 through June 2026 came in at 0.1%, 2.8%, 3.1%, 5.8%, 8.2% and 9.3%. The latest quarter brought in $9.29 billion, and net income of $1.97 billion was up 9.2% from a year earlier.
For a $212 billion company that sells a product used in almost every plant, that is a real change. Full-year revenue was $34.0 billion in 2025, up 3% from $33.0 billion in 2024, and in 2023 it had actually slipped 1.5%. A run-rate near $37.2 billion, if the latest quarter held, would be about 9% above last year’s total.
What I cannot tell from the data I checked is how much of the acceleration is price, how much is volume, and how much is currency or Engineering project timing. That split matters, because price increases in a contract business can be sticky while a one-off project bump is not. The company’s filings break the drivers out, and I would read that page before leaning on the trend.
Profit grew faster than sales
The longer record says something different from the recent quarters. From 2022 to 2025, revenue rose from $33.4 billion to $34.0 billion, about 2%. Over the same span, operating income went from $6.46 billion to $9.25 billion, and diluted earnings per share went from $8.23 to $14.61, an increase of roughly 78%.
| Year | Revenue | Operating income | Operating margin | Diluted EPS |
|---|---|---|---|---|
| 2022 | $33.4 billion | $6.46 billion | 17.3% | $8.23 |
| 2023 | $32.9 billion | $8.11 billion | 25.6% | $12.59 |
| 2024 | $33.0 billion | $8.60 billion | 27.4% | $13.62 |
| 2025 | $34.0 billion | $9.25 billion | 27.5% | $14.61 |
Nearly all of that came from margin. Gross margin rose from 41.7% in 2022 to 48.8% in 2025, and the operating margin climbed about ten points. In 2023 alone it jumped from 17.3% to 25.6% on flat revenue. Then, in 2024 and 2025, the margin barely moved, which means the earnings growth of the last two years is close to the growth of sales plus a little.
That reframes the recent acceleration. The old engine, margin expansion, has mostly run out. What is left is volume and price, and the last two quarters suggest those are picking up. If revenue growth holds near 9% with a margin holding near 27.5%, earnings growth of 9% to 12% is a reasonable expectation. The forward estimate of $17.35 per share against $15.50 over the last twelve months implies about 12%, so the market data agrees.
A discount to itself, not to the market
At 29.7 times earnings, Linde sits near the bottom of its own five-year range, where the average is 36.9. The specialty chemical group averages about 28.7, so against that group it is priced in line. The forward price-to-earnings ratio is 26.5.
So here is my read. A 20% discount to its own average is real, but that average was set when the company was expanding margins by a point or two a year. Paying 36.9 times for that growth made more sense than paying 36.9 for 9% growth on a stable margin. I would say the fair comparison today is the group average of 28.7, and against that Linde is not a bargain.
It is also worth setting the multiple beside other quality names. I wrote about Microsoft at 27.5 times earnings, and Linde now trades at a similar number with much slower revenue growth than a cloud business, though with steadier demand. In my ranking of large retailers, the lesson was similar: a premium multiple is easier to accept when the revenue is predictable, and Linde’s is.
Why the shares keep dropping after reports
Look at the last six earnings days in the data. Shares moved -5.9% on July 31, 2026, +1.4% on May 1, -2.9% on February 5, -2.7% on October 31, 2025, -0.2% on August 1, 2025, and -1.1% on May 1, 2025. Five of six were down. The average absolute move is 3.2%, so the July drop was nearly double the norm.
I do not have a source that explains those reactions, so I will not assign a cause. What I can say is that the price path fits the puzzle. The monthly close was about $517 in June 2026 and $460 by mid-September, roughly 11% lower, while revenue growth was improving. Either the market expects the growth to fade, or holders who bought for stability have been moving elsewhere. Both explanations are guesses.
Only 1.2% of the float is sold short, so this is not a crowded bet against the company. Thirteen analysts cover the stock, 85% rate it Buy, and the average target is $560, 22% above the price, with a range from $525 to $612. Even the lowest target is 14% above today’s price. Analyst targets tend to trail price rather than lead it, so I treat them as a description of sentiment, not a forecast.
The dividend is safe and small
Linde paid $6.20 per share over the last twelve months, a yield of 1.35%. Against diluted earnings of $14.61 for 2025, that is a payout of about 42%, and against the forward estimate it is about 36%. There is room to keep raising it.
But this is not an income stock. A 1.35% yield is small next to the cash returns available elsewhere, so the dividend cannot be the reason to own it. The return case is earnings growth, plus whatever multiple the market decides to pay. A holder who needs income should look somewhere else, and I would rather say so plainly.
What would prove me wrong
I could be wrong in two directions. If the acceleration is mostly Engineering project revenue or currency, then the 9.3% figure overstates the trend, growth slips back toward 3%, and a multiple near 30 would look full. That is the risk in the bear case. In the other direction, if the next few quarters show growth holding above 8% with margins near 27.5%, the multiple could drift back toward the 36.9 average, and at the current earnings run-rate that would put the price near $570, close to the top of the analyst range. That is arithmetic, not a forecast.
Weak spots in the data matter too. The quantitative rating from the data provider slipped from C to D over the recent period, which shows how mixed the signals are. The stock also trades 15.7% below its high while earnings are higher than a year ago, and that gap is the whole opportunity if you believe the business is stable.
The report that would decide it
The number I would watch in the next quarterly report is revenue growth excluding Engineering. If it stays above 7% and the operating margin stays at or above 27%, I would call the drop since June an overreaction and a price near $460 reasonable for a business growing earnings around 10% a year. If growth falls below 5%, I would rather wait than pay 29.7 times earnings for the story.
I would not buy on the discount to the five-year average alone, since I think the average is the wrong yardstick. I would buy, or add, only if the growth holds, and the report would tell me within a quarter.
Analysis and opinion only, not investment advice. Figures come from Linde’s filings on SEC EDGAR and its investor site; market data and valuation multiples are approximate and were checked on September 18, 2026.
Sources: Dividends (SEC Investor.gov glossary) (https://www.investor.gov/introduction-investing/investing-basics/glossary/dividend) · Dividends tax topic (IRS) (https://www.irs.gov/taxtopics/tc404)